Menarini Silicon Biosystems Company
Menarini Silicon Biosystems offers unique rare cell technologies and solutions that provide clinicians, clinical researchers, and pharma companies with access to unparalleled resolution in the study of cells and their molecular characterization.
CELLSEARCH® is the first and only clinically validated blood test cleared by the FDA for detecting and enumerating Circulating Tumor Cells (CTCs) to aid in managing patients with metastatic breast, prostate, and colorectal cancers when used in conjunction with other clinical methods (for full intended use see documents.cellsearchctc.com).
DEPArray™ PLUS (for Research Use Only) is an image-based digital cell-sorting and isolation platform that enables clinical researchers to study rare cells with single-cell precision.
The integration of CELLSEARCH® and DEPArray™ technologies provides the most comprehensive cell-based liquid biopsy workflow for the enumeration, sorting, and molecular characterization of rare circulating tumor cells with single-cell precision.
The company Global Biopharma Lab Services offers unique, specialized tools to expedite drug discovery and development programs from preclinical through Phase IV trials. Two Lab locations, in the United States and Europe, support multicenter, global clinical trials and accept samples from around the world.
Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley, PA, US, is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.